Explore Inovio Pharmaceuticals' Q2 2025 earnings call highlights, including progress on INO-3107, regulatory milestones, financial updates, and ...

Merck KGaA is in the investment-grade market Tuesday, a day after holding investor calls, to help fund its $3.9 billion ...

Immunome's varegacestat shows promising efficacy in desmoid tumors, with phase 3 topline data expected by 2025-end. Read why ...

Mount Gambier hosts a full 12-race program this Sunday, August 10, 2025, with the first event jumping at 12:42pm AEST. The meeting offers a mix of maiden, g ...

In Q2 2025, the global pharma sector experienced a decline in M&A activity, with deals worth $32.9 billion, down 11.6% from Q1. Deal volume fell 12.8% to 130. Oncology led with 51 deals. Discover key ...

Merck & Co., Inc. (NYSE: MRK) is one of the best depressed stocks to buy in 2025. On August 2, the company completed the ...